Evidence map›Paper›PMID 34231643›Full record

ReviewNatural product reports2022

Alternative metabolic pathways and strategies to high-titre terpenoid production in

Mauro A Rinaldi, Clara A Ferraz, Nigel S Scrutton

Open access · hybridAbstract readReview
In one paragraph

Review in Natural product reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 101 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Strategies for Metabolic Engineering ofMolecules (Basel, Switzerland) · 2026
    Review
  7. Article
  8. Article
  9. Enhanced isoprenoid production inBiochemistry and biophysics reports · 2025
    Article
  10. Review
  11. ACS synthetic biology · 2025
    Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Characterization of the Cubamyces Menziesii Terpenome.Chembiochem : a European journal of chemical biology · 2025
    Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Mauro A RinaldiManchester Institute of Biotechnology, Department of Chemistry, School of Natural Sciences, The University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK. nigel.scrutton@manchester.ac.uk.ORCID 0000-0001-7087-1184
Clara A FerrazManchester Institute of Biotechnology, Department of Chemistry, School of Natural Sciences, The University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK. nigel.scrutton@manchester.ac.uk.ORCID 0000-0003-2628-8412
Nigel S ScruttonManchester Institute of Biotechnology, Department of Chemistry, School of Natural Sciences, The University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK. nigel.scrutton@manchester.ac.uk.ORCID 0000-0002-4182-3500
University of Manchester · GB

Funding

Biotechnology and Biological Sciences Research Council BB/S011684/1
6 · The paper itself

Abstract

Covering: up to 2021Terpenoids are a diverse group of chemicals used in a wide range of industries. Microbial terpenoid production has the potential to displace traditional manufacturing of these compounds with renewable processes, but further titre improvements are needed to reach cost competitiveness. This review discusses strategies to increase terpenoid titres in

Indexed as

Metabolic EngineeringMetabolic Networks and PathwaysEscherichia coliTerpenesTerpenes

Identifiers

PMID34231643
PMCPMC8791446
OpenAlexW3181385252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.